Abstract
Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality and is the most common cause of death from infectious diseases. Severe CAP (SCAP) patients that required ICU admission carry the highest mortality rates. Multiple sets of clinical practice guidelines have been published in the past few years addressing the treatment of CAP, and they all agree that CAP patients admitted to the hospital represent a major concern, and appropriate empiric therapy should be instituted to improve clinical outcomes. The purpose of this article is to review the current literature regarding the optimal empiric selection of antibiotic therapy for patients with SCAP. In addition emphasis on the empiric and direct therapy will be made on patients with bacteremic pneumococcal pneumonia.
Keywords: Pneumonia, antibiotics, S. pneumoniae
Current Respiratory Medicine Reviews
Title: Optimal Treatment of Severe Community-Acquired Pneumonia
Volume: 3 Issue: 3
Author(s): Grant W. Waterer and Marcos I. Restrepo
Affiliation:
Keywords: Pneumonia, antibiotics, S. pneumoniae
Abstract: Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality and is the most common cause of death from infectious diseases. Severe CAP (SCAP) patients that required ICU admission carry the highest mortality rates. Multiple sets of clinical practice guidelines have been published in the past few years addressing the treatment of CAP, and they all agree that CAP patients admitted to the hospital represent a major concern, and appropriate empiric therapy should be instituted to improve clinical outcomes. The purpose of this article is to review the current literature regarding the optimal empiric selection of antibiotic therapy for patients with SCAP. In addition emphasis on the empiric and direct therapy will be made on patients with bacteremic pneumococcal pneumonia.
Export Options
About this article
Cite this article as:
Grant W. Waterer and Marcos I. Restrepo , Optimal Treatment of Severe Community-Acquired Pneumonia, Current Respiratory Medicine Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339807781387553
DOI https://dx.doi.org/10.2174/157339807781387553 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preparation and Preliminary Evaluation of <sup>68</sup>Ga-Acridine: An Attempt to Study the Potential of Radiolabeled DNA Intercalator as a PET Radiotracer for Tumor Imaging
Anti-Cancer Agents in Medicinal Chemistry Pleiotropic Effects of Statins in Atherosclerotic Disease: Focus on the Antioxidant Activity of Atorvastatin
Current Topics in Medicinal Chemistry Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Astrocyte Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the Pathogenesis of HIV-1-Associated Dementia
Current HIV Research Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Cholinesterase Inhibitors and Beyond
Current Alzheimer Research AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients
Current Proteomics Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines
Current Alzheimer Research Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Neuroinflammatory Markers in Spontaneously Hypertensive Rat Brain: An Immunohistochemical Study
CNS & Neurological Disorders - Drug Targets HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
Current HIV Research Nanotechnology Based Delivery Systems of Drugs Currently Used to Treat Alzheimer’s Disease
Nanoscience & Nanotechnology-Asia Antidepressant-Like Activity of Fish Oil, with and Without Fluoxetine, in Two Behavioral Despair Paradigms in Experimental Mice
Current Pharmacogenomics and Personalized Medicine A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets